We invest where the science is real and the chemistry is unfinished.
Taiho Ventures invests in biotech companies between preclinical work and proof of concept. We focus on oncology, immunology, and urology.
We are the corporate venture arm of Taiho Pharmaceutical, a Japanese specialty pharmaceutical company and a subsidiary of Otsuka Holdings Co., Ltd.
The fund is $400 million and patient. The parent is patient, so the fund is patient.
Therapeutic area × clinical stage
Each cell shows active positions. The red cell marks the area where the fund is most engaged this quarter.
What the fund will and will not consider
- Drug discoveryfirst-in-class or new biology
- Platform technology
- Taiho pipeline spin-outs
- Devices · diagnostics · digital healthopportunistic
- Oncology
- Immunology · allergy
- Urology
- Bone · muscle · orphan
- Small molecules
- Biologics
- Gene · cell therapy
- Research → Pre-INDprimary
- IND → Proof of conceptopportunistic
23 active positions
Listed in alphabetical order. Stage reflects most-recent disclosed milestone.
We participate in syndicates. We do not usually lead them.
We participate in syndicates. We do not usually lead them.
Capital is the easy part. Putting a global pharmaceutical company on a biotech's cap table is the hard part — that is the work the fund exists to do.